Effect of sorafenib combined with daunorubicin on K562 cell line.
- Author:
Ruo-Zhi XIAO
1
;
Li-Lin WANG
;
Xing-Xing RUAN
;
Cheng-Ming HE
;
Yan CHEN
;
Dong-Jun LIN
Author Information
1. Institute of Hematologic Diseases, SUN Yat-Sen University, Guangdong Province, China. ruozhi_xiao@yahoo.com
- Publication Type:Journal Article
- MeSH:
Apoptosis;
drug effects;
Benzenesulfonates;
pharmacology;
Daunorubicin;
pharmacology;
Drug Synergism;
Humans;
K562 Cells;
Niacinamide;
analogs & derivatives;
Phenylurea Compounds;
Pyridines;
pharmacology
- From:
Journal of Experimental Hematology
2010;18(3):621-624
- CountryChina
- Language:Chinese
-
Abstract:
The aim of this study was to investigate the effect of sorafenib combined with daunorubicin on leukemic k562 cell line. The inhibitory effect of sorafenib alone and its combination with daunorubicin on K562 cell proliferation was detected by MTT method; the synergistic effect was measured by CDI (coefficient of drug interaction); the apoptosis of K562 cells was observed by flow cytometry with Hoechst 33258 staining. The results showed that the sorafenib alone or its combination with daunorubicin could significantly inhibit K562 cell proliferation and the combination of both drugs displayed synergistic effect on K562 cells, meanwhile the apoptotic cells increased. It is concluded that the combination of sorafenib and daunorubicin has a obviously synergistic inhibitory effect on leukemic cell line K562.
